

ASX Announcement

BCAL Diagnostics Expands Access to BREASTEST *plus*™ Across Sydney and Melbourne

Highlights

- Agreement reached to offer BREASTEST *plus*™ at three additional specialist breast clinics across Sydney and Melbourne, commencing mid-May 2025;
- Aligned with BCAL's national rollout strategy focused on improving early detection in women with high breast density as part of comprehensive screening.

Sydney, Australia, 6 May 2025 – BCAL Diagnostics Limited, (ASX: BDX, BCAL, the Company) an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics today announced access to BREASTEST *plus*™, its blood test to rule out the presence of breast cancer in women with high breast density, has expanded to additional sites in Sydney and Melbourne.

Following the successful commercial launch in March 2025, BREASTEST *plus*™ will be available at three additional specialist clinics including the Strathfield Breast Centre at Strathfield Private Hospital and Lakeside Specialist Breast Clinic at Lakeview Private Hospital in Sydney, and Southern Breast Oncology in Bentleigh East, Melbourne.

This expansion is aligned with BCAL's rollout strategy, focused on improving early breast cancer detection for women with high breast density—a group where mammography is often more difficult to detect with traditional imaging due to masked lesions and imaging challenges. Women with high breast density are also more at risk of developing breast cancer.

Professor Elisabeth Elder, Specialist Breast and Oncoplastic Surgeon at Lakeview Private Hospital in Sydney, commented: "We are delighted to be working with BCAL to offer BREASTEST *plus*™ as part of regular breast screening for women aged 30 and over with high breast density. This test helps to bridge diagnostic gaps where mammography performance is limited, or the imaging is unclear – which is common in women with high breast density. Incorporating BREASTEST *plus*™ into routine practice is an important step toward improving early and accurate diagnosis for this group of women."

BCAL Diagnostics Chief Executive Officer, Shane Ryan said: "Our commercial rollout continues to progress in line with our expansion and market access plans. Expanding access across Sydney and Melbourne represents a significant milestone in ensuring more women benefit from this breakthrough diagnostic tool. We remain focused on partnering with breast specialists and delivering a systematic rollout throughout 2025."

Women interested in accessing BREASTEST *plus*™ are encouraged to speak with their breast specialist.

Further information is available at www.bcaldiagnostics.com. Alternatively, contact info@bcaldiagnostics.com or speak to a member of the BCAL support team regarding any questions related to BREASTEST *plus*™ at 1300BCALDX (1300 222 539).

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

Jayne Shaw
Executive Chair
Jshaw@bcaldiagnostics.com

Shane Ryan
Chief Executive Officer
Sryan@bcaldiagnostics.com

Investor & Media Enquiries
Tanya Thomas
Director Investor Relations &
Communications
Tthomas@bcaldiagnostics.com

About BREASTEST *plus*™

BREASTEST *plus*™ is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*™ is a first in class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST *plus*™ is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

About BCAL Diagnostics

BCAL Diagnostics is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and providing their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces the need for further investigation and biopsy resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.